MIZUHO MEDY CO.,LTD.
4595 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 鳥栖市藤木町５番地の４
- Website:
- https://www.mizuho-m.co.jp/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MIZUHO MEDY Co., Ltd., based in Tosu, Saga, Japan, specializes in in vitro diagnostics, offering a comprehensive range of innovative products. The company is renowned for its advanced nucleic acid amplification tests and rapid immunoassays catering to clinical, research, and agricultural applications. Notable offerings include the Smart Gene® series and the Quick Chaser line, which addresses various pathogens, including SARS-CoV-2 and RSV. Committed to quality, MIZUHO MEDY has achieved ISO 13485 certification for its operations, ensuring adherence to stringent quality management standards. With a focus on technological advancement, the company actively participates in international exhibitions, showcasing its commitment to healthcare innovation and improving diagnostic solutions.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-04-02 06:17 |
Inside Information Statement
臨時報告書
|
Japanese | 25.9 KB | |
| 2025-03-31 03:44 |
Internal Control over Financial Reporting
内部統制報告書－第48期(2024/01/01－2024/12/31)
|
Japanese | 22.5 KB | |
| 2025-03-31 03:41 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-03-31 03:37 |
Annual Report
有価証券報告書－第48期(2024/01/01－2024/12/31)
|
Japanese | 931.6 KB | |
| 2024-08-09 06:11 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-08-09 06:09 |
Interim Report
半期報告書－第48期(2024/01/01－2024/12/31)
|
Japanese | 209.8 KB | |
| 2024-05-10 06:07 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-05-10 06:06 |
Quarterly Report
四半期報告書－第48期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 169.5 KB | |
| 2024-04-01 09:48 |
Inside Information Statement
臨時報告書
|
Japanese | 21.6 KB | |
| 2024-03-29 02:02 |
Internal Control over Financial Reporting
内部統制報告書－第47期(2023/01/01－2023/12/31)
|
Japanese | 22.5 KB | |
| 2024-03-29 01:59 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-03-29 01:56 |
Annual Report
有価証券報告書－第47期(2023/01/01－2023/12/31)
|
Japanese | 967.0 KB | |
| 2023-11-10 05:09 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2023-11-10 05:07 |
Quarterly Report
四半期報告書－第47期第3四半期(2023/07/01－2023/09/30)
|
Japanese | 171.4 KB | |
| 2023-08-10 06:09 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |